Please login to the form below

Not currently logged in
Email:
Password:

Wellcome Trust director Sir Mark Walport named UK’s chief scientific adviser

Will provide scientific advice direct to Prime Minister David Cameron and the cabinet

The director of research charity the Wellcome Trust Sir Mark Walport has been appointed chief scientific adviser to the UK government.

Taking up his new post in April, 2013, Sir Mark will replace Sir John Beddington in providing advice directly to Prime Minister David Cameron and the cabinet concerning scientific issues.

“Science, engineering and technology have transformed the infrastructure of the modern world, and have a vital role to play at the heart of policy making,” said Sir Mark.

"They are critical both to economic recovery and growth, and to addressing many of the greatest challenges of our time, such as environmental change and the ageing population.”

With a background in immunology, Sir Mark will play a key role in the implementation of the £180m worth of life sciences reforms in the UK announced by Cameron at the end of 2011.

He will also work with ministers, the scientific community and the media to ensure that scientific methods, risk and uncertainty are understood by the public.

Sir Mark had been director of the Wellcome Trust since 2003, leading the body in its support of scientific and medical research.

This included studies into the human genome and human brain, infectious diseases such as malaria and MRSA, and chronic diseases such as diabetes and cancer.

The Trust's chair Sir Bill Castell is to lead the board of governors in the recruitment of a new director.

He said: "Mark has led the Wellcome Trust with great distinction over a decade of extraordinary achievement, and there is nobody in Britain better placed to ensure that science plays the central role it deserves to in public policy. British science will be stronger for his appointment.”

5th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CreateHealth.io

We connect companies to customers through online and offline events. Our proprietary customer insight platform, and expert staff in stakeholder...

Latest intelligence

When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....
Forecasting for Licensed Compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharmaceutical forecasting...

Infographics